ReviewFrontiers in immunology2021
Sensitization and Desensitization in Vascularized Composite Allotransplantation.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Bio-boosting transplants: a systematic review on biopolymers in vascular composite allotransplantation.Frontiers in immunology · 2025Pooled it
- Facial vascularized composite allotransplantation: Mapping global research trends and scientific impact.JPRAS open · 2026Review
- Rituximab-based Induction in Vascularized Composite Allotransplantation: Prolonged Rejection-free Survival and the Role of Donor-specific Antibodies.Plastic and reconstructive surgery. Global open · 2026Article
- A review of immunosuppressive therapy in the context of uterine VCA and pregnancy.Frontiers in transplantation · 2026Review
- Laryngeal transplantation: from experimental feasibility to multidisciplinary clinical reality.Frontiers in surgery · 2026Review
- Urinary bladder transplantation in humans - current status and future perspectives.Nature reviews. Urology · 2025Review
- Exploring Costimulatory Blockade-Based Immunologic Strategies in Transplantation: Are They a Promising Immunomodulatory Approach for Organ and Vascularized Composite Allotransplantation?Journal of personalized medicine · 2024Review
- Immunogenicity and tolerance induction in vascularized composite allotransplantation.Frontiers in transplantation · 2024Review
- Novel Human Umbilical Di-Chimeric (HUDC) cell therapy for transplantation without life-long immunosuppression.Stem cell investigation · 2023Article
- Cellular activation pathways and interaction networks in vascularized composite allotransplantation.Frontiers in immunology · 2023Review
- Potential Roles of miRNAs in Acute Rejection for Vascularized Composite Allotransplantation.Journal of inflammation research · 2022Article
- The future role of mitochondrial drugs in vascularized composite allotransplantation: A short review.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascularized composite allotransplantation (VCA) is a field under research and has emerged as an alternative option for the repair of severe disfiguring defects that result from severe tissue loss in a selected group of patients. Lifelong immunosuppressive therapy, immunosuppression associated complications, and the effects of the host immune response in the graft are major concerns in this type of quality-of-life transplant. The initial management of extensive soft tissue injury can lead to the development of anti-HLA antibodies through injury-related factors, transfusion and cadaveric grafting. The role of antibody-mediated rejection, donor-specific antibody (DSA) formation and graft rejection in the context of VCA still remain poorly understood. The most common antigenic target of preexisting alloantibodies are MHC mismatches, though recognition of ABO incompatible antigens, minor histocompatibility complexes and endothelial cells has also been shown to contribute to rejection. Mechanistically, alloantibody-mediated tissue damage occurs primarily through complement fixation as well as through antibody-dependent cellular toxicity. If DSA exist, activation of complement and coagulation cascades can result in vascular thrombosis and infarction and thus rejection and graft loss. Both preexisting DSA but especially
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.